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Received February 3, 2012; accepted May 21, 2012AbstractBackground: It is a well-accepted fact that angiotensin II (Ang II) contributes to increased vascular tone in cirrhotic livers. However, aliskiren
attenuates the effect of Ang II through direct renin inhibition. Our study aimed to evaluate the effects of aliskiren on portal pressure and
intrahepatic resistance in bile duct ligated (BDL) rats.
Methods: The effects of acute intravenous infusion (1 mg or 3 mg) or a course of 2-day oral administration of aliskiren (20 mg/kg/day) on blood
pressure and portal pressure were evaluated in BDL and sham rats. Intrahepatic resistance was evaluated by a liver perfusion study isolated in
situ. Ang II efflux was measured by Enzyme-linked immunosorbent assay (ELISA). The hepatic gene expression of angiotensinogen, renin,
angiotensin-converting enzyme (ACE), Ang II type 1 receptor (AT1R) was analyzed with quantitative reverse transcription polymerase chain
reaction.
Results: Aliskiren infusion intravenously reduced portal pressure with a minimal effect on blood pressure in BDL rats. Direct infusion of
aliskiren in an isolated cirrhotic liver caused greater vasorelaxation and decreased hepatic production of Ang II. Two days of aliskiren treatment
reduced portal pressure and hepatic ACE mRNA; in addition, it improved the vasodilator response to acetylcholine in the cirrhotic livers and
decreased Ang II efflux.
Conclusion: Aliskiren reduced portal pressure in cirrhotic rats. The portal hypotensive effect of aliskiren was related to the amelioration of the
Ang II induced intrahepatic vasoconstriction.
Copyright  2012 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Increased hepatic resistance to portal blood inflow is the
initial hemodynamic derangement that contributes to portal
hypertension in cirrhosis. Thereafter, an increased portal blood
inflow maintains and worsens portal hypertension.1 Increased* Corresponding author. Dr. Kuei-Chuan Lee, Division of Gastroenterology,
Department of Medicine, Taipei Veterans General Hospital, 201, Section 2,
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http://dx.doi.org/10.1016/j.jcma.2012.07.001intrahepatic resistance (IHR) is mainly caused by the disrup-
tion of the vascular architecture due to an irreversible struc-
tural change in cirrhotic livers. Additionally, an enhancement
in intrahepatic vascular tone also contributes to the increased
IHR.2 As IHR increases, the increased portal resistance results
in dilatation of the mesenteric and systemic vasculature and
decreases the effective blood volume. A compensatory change
that restores the effective blood volume is the activation of the
renin-angiotensin-aldosterone system (RAS).
The RAS plays an important role in the regulation of local
hemodynamics in a cirrhotic liver.3 The primary effectorhinese Medical Association. All rights reserved.
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rats, the hepatic expression of angiotensin type I receptor
(AT1R) and plasma Ang II concentration has been shown to
increase significantly when compared with those in healthy rat
livers.4,5 Administration of Ang II also increases intrahepatic
vascular resistance in cirrhosis,4,6 while treatment with Ang II
receptor blockers has the opposite effect.7,8 Therefore, as the
action of Ang II in the cirrhotic liver contributes to the
increase of IHR,9 inhibition of Ang II production is a rational
way to decrease IHR.
Renin, which cleaves liver-produced angiotensinogen to
angiotensin I (Ang I), is the first rate-limiting enzyme in the
synthesis of Ang II.10 Inhibition of renin activity has been
a potential way to down-regulate the RAS. Recently, a direct
renin inhibitor, aliskiren, had been approved for treatment of
hypertension.10 Aliskiren occupies the active site of renin11 to
block the enzyme activity of renin. This effect leads to lower
plasma renin activity, plasma Ang I, and Ang II.12,13 We
hypothesized that aliskiren may lower the production of Ang II
in cirrhotic rat livers and subsequently reduce IHR. To date,
there has been no data published regarding the effects of
aliskiren on IHR in cirrhosis. The aim of this study is to
investigate the possible effects of aliskiren on portal pressure
and IHR in a bile duct ligated cirrhotic rat model.
2. Methods2.1. AnimalsAdult male Sprague Dawley rats (BioLasco Taiwan Co.,
Ltd, Taipei, Taiwan) were used in all experiments. Cirrhotic
rats were created by bile duct ligation (BDL) as previously
described.14 The rats underwent median laparotomy with the
common bile duct exposed, but without ligation and served as
the control (sham rats). According to the previous findings, the
expression of AT1R in liver and Ang II levels in plasma
increased dramatically in the BDL rats 4 weeks after ligation
of the common bile duct.4 The BDL rats after 4 weeks were
thereafter used for the experiment. This study was approved by
the Animal Experiment Committee of Taipei Veterans General
Hospital and performed according to the Guide for the Care
and Use of Laboratory Animals prepared by the U.S. National
Academy of Sciences.2.2. Experimental protocol
2.2.1. Experiment I: Evaluation of the effects of acute
intravenous administration of aliskiren on arterial pressure
and portal pressure
In a previous study, it was found that aliskiren dose-
dependently decreased blood pressure in spontaneously
hypertensive rats.15 In this pharmacokinetic study, the rats
receiving 30 mg/kg aliskiren orally or 3 mg/kg aliskiren
intravenously showed similar plasma concentration-time
profiles.15 When the experiments began, we administered
aliskiren (Novartis Pharmaceuticals, East Hanover, NJ, USA)
10 mg/kg intravenously to the BDL rats; however, dramatichypotension was noted. Therefore, in the subsequent study, the
rats (n ¼ 5 in each sham group, n ¼ 7 in each BDL group)
were given smaller doses of aliskiren (1 or 3 mg/kg, intrave-
nously), which had a more modest effect on systemic blood
pressure.
The hemodynamic studies were performed by catheteriza-
tion method. With the rats sedated by pentobarbital (50 mg/kg,
intraperitoneally), the femoral artery and vein were cannulated
with PE-50 (ADInstruments, Inc, Colorado, USA) tubing to
monitor blood pressure and infuse drugs. The portal vein was
cannulated via an ileal vein for the measurement of portal
venous pressure (PVP). The rectal temperature was maintained
at 37C using a heating pad. All pressures were recorded using
a multichannel recorder (BIOPAC Systems, Inc, CA, USA).
After an initial stable period, the basal values were obtained.
One mg/kg or 3 mg/kg aliskiren in 1 ml 5% dextrose water
(D5W) was then injected for 10 minutes via the femoral vein
through an automatic pump. Blood pressure and PVP were
concomitantly monitored and recorded for 60 minutes.
2.2.2. Experiment II: Evaluation of the effects of direct
infusion of aliskiren on intrahepatic resistance in an in situ
liver perfusion system
The second set of BDL rats and sham rats (n ¼ 4 in each
group) were used in this experiment. The in situ liver perfu-
sion was performed in a recirculating system as previously
described.14 The flow rate of the perfusate was 25 ml/minute.
The viability of each liver was assessed by gross appearance of
the liver, bile production, and curve pattern of portal perfusion
pressure (PPP). The livers were allowed to stabilize for 30
minutes before basal PPP was measured.
After basal measurements of PPP, 104 M methoxamine
(MTX) was added to the perfusate for preconstriction 5
minutes before the challenge of sequential doses of aliskiren
(109 to 104 M) or D5W. Then, the concentration-responded
curve of PPP to aliskiren or vehicle was measured. Before the
MTX administration, and after aliskiren or vehicle adminis-
tration, each 3 ml of effluent was collected for further
measurement of Ang II. All livers were weighed after the
experiment. The absolute increase of Ang II levels in liver
perfusates after drugs administration was expressed in pg/ml/
gm of liver weight. The response to aliskiren or vehicle was
calculated as the percentage change of PPP from baseline.
2.2.3. Experiment III: Evaluation of the effects of oral
administration of aliskiren on blood pressure, PVP, and
IHR
Because the effect of aliskiren was most apparent at 24 and
48 hours. After drug intake,13,16 we performed another
hemodynamic study 2 days after administration of aliskiren.
Thus, the third set of BDL rats were treated orally with alis-
kiren (20 mg/kg/day, BDL-Alil n ¼ 8) or vehicle (BDL-V;
n ¼ 8). The sham rats receiving aliskiren (sham-Ali; n ¼ 5) or
vehicle (sham-V; n ¼ 5) were used for comparison. After
measurement of arterial blood pressure and PVP, the rats
received the in situ liver perfusion study, which ran in
a recirculating system at a constant flow (25 ml/minute). Each
Table 1




Gapdh Forward 50- TGTTGAAGTCACAGGAGACAACCT -30 111 bp
Reverse 50- AACCTGCCAAGTATGATGACATCA -30
Agt Forward 50- GCCCAGGTCGCGATGAT -30 63 bp
Reverse 50- TGTACAAGATGCTGAGTGAGGCAA -30
Agtr1a Forward 50- CGGCCTTCGGATAACATGA -30 67 bp
Reverse 50- CCTGTCACTCCACCTCAAAACA -30
Ren Forward 50- AACATTACCAGGGCAACTTTCACT -30 73 bp
Reverse 50- ACCCCCTTCATGGTGATCTG -30
ACE Forward 50- CACCGGCAAGGTCTGCTT -30 97 bp
Reverse 50- CTTGGCATAGTTTCGTGAGGAA -30
ACE ¼ angiotensin I converting enzyme; Agt ¼ angiotensinogen;
Agtr1a ¼ angiotensin II receptor, type 1a; Gapdh ¼ glyceraldehyde-3-
phosphate dehydrogenase; Ren ¼ renin; QPCR ¼ quantitative polymerase
chain reaction.
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after stabilization to estimate the basal production of Ang II.
The basal production rate of Ang II in liver perfusates was
expressed in pg/ml/minute/g of liver weight. Afterward, the
responses of PPP to MTX (104 M) were measured, both
before and subsequent to the cumulative doses of acetylcho-
line (Ach; 107e104 M). The relaxation response to Ach was
calculated as the percentage change of PPP from baseline.
2.2.4. Experiment IV: Evaluation the effect of aliskiren on
blood and liver biochemistry
The fourth set of BDL/sham rats was treated orally with
aliskiren (20 mg/kg/day) or vehicle (n¼ 5 in each group). After
this step was completed, the rats were sacrificed. Blood samples
were collected on ice with tubes containing 0.1 M sodium
citrate. Plasma was separated by refrigerated centrifugation and
processed immediately or stored at80C until assay. The liver
was rapidly excised and weighted after ice-cold phosphate
buffered saline (PBS) perfusion. Aliquots of liver were snap
frozen in liquid nitrogen and kept at 80C until analysis.
The plasma levels of aspartate aminotransferase (AST),
alanine aminotransferase (ALT), alkaline phosphatase (ALK-
P) total bilirubin (TB), blood urea nitrogen (BUN), creatinine
(Cr), sodium (Na), and potassium (K) were measured using
a standard auto-SMAC analyzer (Roche Diagnostics GmbH,
Mannheim, Germany).2.3. Measurements of Ang II in liver perfusatesThe perfusates collected from the in situ liver perfusion
study were measured for the content of Ang II. The Ang II
levels were determined by the AssayMax Angiotensin II
Enzyme-linked immunosorbent assay (ELISA) kit (AssayPro
Co., St. Charles, MO, USA). This assay has an intra-assay
coefficient of variation of 5.0% and an interassay coefficient
of variation of 7.1%.2.4. Real-time quantitative reverse
transcriptaseepolymerase chain reactionComplementary DNAs were synthesized by reverse tran-
scription of 1 mg of total RNA according to the MMLV reverse
transcriptase first-strand cDNA Synthesis Kit (Epicentre
Technologies Corp., Madison, WI, USA). The primers used
are listed in Table 1. Quantitative gene expression was per-
formed on the ABI PRISM 7900HT Sequence detection
system (Applied Biosystems Inc., Foster City, CA, USA) using
SYBR green (Roche Diagnostics GmbH, Mannheim,
Germany) technology. The expression of target genes was
calculated by the 266CT method. The results were
expressed as fold change relative to the control group.2.5. Statistical analysisData were analyzed by GraphPad Prism 4 (GraphPad
Software, San Diego, CA, USA) and expressed as
means  standard deviation. Kruskal-Wallis test followed byDunn’s test or Mann-Whitney U-test was used for comparison
between groups. Concentration-response curves of PPP were
analyzed by repeated-measure analysis of variance. Signifi-
cance was determined at a p value less than 0.05.
3. Results3.1. Aliskiren infusion reduces portal pressure with
modest effect on arterial blood pressureIn sham groups, the rats receiving aliskiren of 1 mg or 3 mg
exhibited no significant changes of MAP and PVP during the
observation period (Fig. 1A and B). In the BDL groups, both
1mg and 3mg doses of aliskiren caused a transient drop inMAP
during the period of aliskiren infusion (7.44  2.01 mmHg,
9.69 1.54 mmHg respectively; Fig. 1C). However, although
the MAP returned to baseline later and remained stable in the
following period (Fig. 1C), the PVP decreased significantly 50
minutes after the intravenous administration of 1mg aliskiren in
the BDL rats. In BDL rats receiving 3 mg aliskiren, the PVP
decreased significantly from 20 minutes after drug infusion
(Fig. 1D). The 3 mg dosage also had a stronger effect on PVP in
BDL rats comparedwith the 1mgdose ( p¼ 0.0096 by repeated-
measure analysis of variance; Fig. 1D).3.2. Direct effect of aliskiren on intrahepatic resistanceBased on the data from Experiment I, we assumed that the
reduction in PVP may have resulted from a direct influence of
aliskiren on IHR. This prompted us to measure the responses
of liver to the cumulative doses of aliskiren or D5W in the rats
(Fig. 2A). The result was that there was significantly less
vasorelaxation (a smaller percentage reduction of PPP) in both
groups of cirrhotic livers when compared with the sham livers
( p < 0.01). The BDL rat livers receiving sequential doses of
aliskiren had significantly greater vasorelaxation than the BDL
rat livers receiving D5W ( p ¼ 0.002). However, the degree of
vasorelaxation was not significantly different between sham
rat livers receiving aliskiren or D5W. In addition, the absolute
increase in Ang II in BDL rat liver perfusion effluent after
Fig. 1. Acute administration of low doses of aliskiren (Ali) reduces portal pressure without lowering arterial blood pressure in bile duct ligated (BDL) rats. (A,B)
Kinetic change of mean arterial pressure or portal venous pressure in sham rats; or (C,D) BDL rats receiving Ali (1 or 3 mg) infusion through femoral veins. n ¼ 5
in each sham group; n ¼ 7 in each BDL group. *p < 0.05 compared with basal status. **p < 0.01 compared with basal status. yp < 0.01.
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BDL rat livers receiving D5W ( p ¼ 0.035) (Fig. 2B).
Nevertheless, the absolute increases in Ang II in liver perfu-
sion effluents after aliskiren or D5W administration were not
different in the sham rats ( p ¼ 0.26; Fig. 2B).3.3. Effects of oral aliskiren treatment for 48 hours on
hemodynamics and blood chemistryAll cirrhotic rats had portal hypertension, ascites and
splenomegaly. The blood chemistry, and weights of the body
and liver are shown in Table 2. The plasma levels of BUN, Cr,Fig. 2. (A) Dose-response curves to cumulative doses of aliskiren (Ali) or 5% dex
(B) absolute increase of angiotensin II levels in liver perfusates after drug administ
or Ali; BDL-D5W/Ali: BDL rats receiving D5W or Ali; n ¼ 4 in each group.) *p <
rats. PPP ¼ portal perfusion pressure; n.s. ¼ not significant.Na, and K and body weight were not different for the experi-
mental groups. The BDL rats receiving vehicle or aliskiren had
a higher liver weight and higher plasma levels of ALT, AST,
ALKP, and TB than the sham rats receiving vehicle. After
treatment with aliskiren, these parameters remained unchanged.
The MAP was significantly lower in the BDL-V and BDL-
Ali rats than that in the sham-V rats ( p < 0.01; Fig. 3A). After
aliskiren treatment, the MAP remained unchanged in both the
BDL and sham rats. The PVP was significantly higher in the
BDL-V rats than in the sham-V rats ( p < 0.001; Fig. 3B).
However, the BDL-Ali rats had a significantly lower PVP than
the BDL-V rats ( p < 0.01; Fig. 3B).trose water (D5W) in the liver from the sham or bile duct ligated (BDL) rats;
ration in four experimental groups. (Sham-D5W/Ali: sham rats receiving D5W
0.05 compared with BDL-D5W rats. **p < 0.01 compared with BDL-D5W
Table 2
Body and liver weight, and blood biochemistry in rats.
Sham-V Sham-Ali BDL-V BDL-Ali
Body weight (g) 293.8  65.44 292.8  38.50 334.3  48.60 343.3  40.30
Liver weight (g) 11.48  2.19 11.20  2.06 20.59  4.21* 21.98  2.69*
ALT (U/L) 52.40  6.19 42.80  0.84 126.3  16.62* 119.8  33.93*
AST (U/L) 108.6  27.34 82.00  11.81 701.7  329.8* 669.0  186.8*
ALKP (U/L) 163.2  20.60 139.8  33.09 295.0  18.35* 322.0  45.36*
TB (mg/dL) 0.0400  0.0187 0.0340  0.0313 6.110  0.2435* 6.398  1.025*
BUN (U/L) 15.00  1.87 15.60  1.67 13.67  1.03 13.60  3.362
Cr (U/L) 0.2920  0.054 0.2620  0.079 0.1900  0.054 0.1900  0.077
Na (U/L) 162.2  4.92 162.6  3.51 154.4  4.10 160.6  6.19
K (meq/L) 4.920  0.35 5.000  0.76 5.133  0.05 5.160  0.82
All data are expressed as the mean  SD. Ali ¼ aliskiren; ALK-P ¼ alkaline phosphatase; ALT ¼ alanine aminotransferase; AST ¼ aspartate aminotransferase;
BDL-Ali¼ bile duct ligated rats receiving aliskiren administration; BDL-V¼ bile duct ligated rats receiving vehicle; BUN¼ blood urea nitrogen; Cr ¼ creatinine;
K ¼ potassium; Na ¼ sodium; Sham-Ali ¼ sham rats receiving aliskiren administration; Sham-V ¼ sham rats receiving vehicle; TB ¼ total bilirubin.
*p < 0.01 vs. sham-V.
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significantly higher in the BDL-V rats than in the sham-V rats
( p < 0.01). A significant decrease in PPP was also observed in
the BDL-Ali rats compared with the BDL-V rats ( p ¼ 0.035;
Fig. 3C). Responses to accumulative doses of Ach in the four
groups of rats are shown in Fig. 3D. There was significantly
less vasorelaxation in both groups of cirrhotic livers compared
with the sham livers ( p < 0.001). The BDL-Ali rat livers had
significantly more vasorelaxation than the BDL-V rat liversFig. 3. Effects of oral aliskiren (Ali) treatment for 48 hours on portal pressure and
and (C) portal perfusion pressure in four experimental groups; (D) dose-response cu
groups; (E) basal production rate of angiotensin II in liver perfusates from BDL-V/A
receiving vehicle or Ali; n ¼ 5 in each sham group, n ¼ 8 in each BDL group.) *p <
BDL-V. BDL ¼ bile duct ligated.( p ¼ 0.0006). Furthermore, the administration of aliskiren
decreased the basal Ang II production in livers of BDL-Ali
rats ( p < 0.01; Fig. 3E).3.4. Effects of aliskiren on classical RASThe hepatic transcript expressions of angiotensinogen and
renin were not different in all experimental groups (Fig. 4A and
B). In the BDL-V rats, hepatic transcript expressions of ACE andintrahepatic resistance. (A) Mean arterial pressure; (B) portal venous pressure;
rves to cumulative doses of acetylcholine in livers from rats in all experimental
li rats. (Sham-V/Ali: sham rats receiving vehicle or Ali; BDL-V/Ali: BDL rats
0.05 vs. sham-V. **p < 0.01 vs. sham-V. yp < 0.05 vs. BDL-V. zp < 0.01 vs.
Fig. 4. The effect of aliskiren (Ali) on the expression of renin angiotensin system. The hepatic gene expression of angiotensinogen (A), renin (B); angiotensin
converting enzyme (C); and angiotensin II receptor type 1; and (D) in all groups. (Sham-V/Ali: sham rats receiving vehicle or Ali; BDL-V/Ali: BDL rats receiving
vehicle or Ali; n ¼ 5 in each group.). **p < 0.01 vs. sham-V. yp < 0.05 vs. BDL-V. BDL ¼ bile duct ligated.
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the sham-V rats ( p¼ 0.008 and p¼ 0.0002, respectively; Fig. 4C
andD). After aliskiren treatment, although the hepatic expression
ofACEdecreased significantly ( p¼ 0.03; Fig. 4C), hepaticAT1R
mRNAwas not altered ( p ¼ 0.07; Fig. 4D).
4. Discussion
Currently, there are three drug classes that can inhibit the
effects of Ang II in the RAS.10 Both the ACE inhibitors and
angiotensin II receptor blockers (ARBs) have been found
effective for reducing portal pressure in several animal and
human studies.8,17e21 However, the use of ACE inhibitors or
ARB in cirrhotic patients remains controversial,3 because
some clinical studies have shown that these drugs produce
only a modest reduction in portal pressure with significant
arterial hypotension.22e24 Aliskiren is the third and new class
of drug that inhibits the RAS. In this study, we observed that
the short-term administration of low-dose aliskiren reduced
portal pressure and intrahepatic resistance associated with
a decreased hepatic production of Ang II in BDL rats.
Importantly, blood pressure was not significantly decreased.
Recently, our colleagues found that aliskiren decreased
portal venous pressure in PVL rats.25,26 In PVL rats, both MAP
and PVP were not reduced after subcutaneous aliskiren treat-
ment at a dose of 10 or 30 mg/kg/day. But MAP and PVP
decreased significantly after treatment at a dose of 50 mg/kg/
day.25 In our current study, the BDL-Ali rats had a significant
decrease in PVP but no reduction of MAP after 2-day oraladministration of aliskiren at a dose of 20 mg/kg/day. Different
routes of drug administration and models may explain the
discrepancy. The oral route used in this study may facilitate
getting aliskiren to the liver more efficiently than the subcuta-
neous route. Moreover, by contrast to the PVL rats that manifest
with presinusoidal portal hypertension and normal IHR, the
BDL rats are characterized by sinusoidal cirrhosis and high IHR.
In our study, theBDL rats receiving a low-dose oral aliskiren had
no significant reduction in MAP. Additionally, the BDL rats
receiving acute intravenous administration of aliskiren exhibi-
ted only an initial transient drop in MAP, and there was a pro-
longed gradual decrease in PVP after return of MAP. Thus, the
portal hypotensive effect of low-dose aliskiren in the BDL rats
may be derived from its beneficial effect on IHR. This indicates
that low-dose oral aliskiren through amelioration of intrahepatic
resistance is effective and safe for the management of portal
hypertension from sinusoidal cirrhosis.
Increased resistance to portal blood inflow in the cirrhotic
liver is partially due to a reversible and dynamically enhanced
intrahepatic vascular tone.9 Research has shown that Ang II is
one of the vasoactive agents contributing to the increased
vascular tone in cirrhotic livers.9 Ballet et al.6 demonstrated
that the intrahepatic vascular resistance was dose-dependently
increased in response to sequential doses of Ang II in isolated
perfused livers of both cirrhotic and normal rats. More
recently, Herath et al.4 also found that cirrhotic rat livers
displayed a marked vasoconstriction response to Ang II. In the
present study, the livers of BDL rats receiving 2-day aliskiren
exhibited less basal production of Ang II and lower PPP when
507Y.-C. Hsieh et al. / Journal of the Chinese Medical Association 75 (2012) 501e508compared with the BDL-V rat livers. Moreover, the vasodi-
latation response to Ach was improved in cirrhotic livers of
BDL-Ali rats. These results suggest that aliskiren attenuated
IHR and subsequently decreased PVP through reduction of the
hepatic production of Ang II.
In the current study, the hepatic gene expression of angio-
tensinogen and renin between the BDL-Vand sham-V rats was
not different. However, the hepatic ACE and AT1R gene
expression were significantly higher in the BDL-V rats than in
the sham-V rats. These results were in accord with previous
research.5 After aliskiren treatment, the gene expression of
angiotensinogen, renin and AT1R remained unchanged,
whereas the ACE mRNA was significantly reduced in the
cirrhotic livers. To our knowledge, there is no evidence that
aliskiren directly lowers the gene expression of renin, ACE, or
angiotensinogen. However, it had been shown that aliskiren
increased renin expression in human plasma or mouse
kidneys.16,27 In our current study, the dose of aliskiren was
small and the duration of administration was short. Therefore,
different species, tissues and dosages used may explain why
the liver renin expression was not altered after aliskiren was
administered. Moreover, it has been reported that in a human
kidney tubular epithelial cell line, Ang II induces ACE gene
and protein expressions in a time and dose-dependent
manner.28 Similarly, in our study, the change of ACE
expression in BDL-V and BDL-Ali rat livers paralleled the
change of hepatic production of Ang II. This suggests that the
decreased ACE expression in BDL-Ali rat livers may result
from the reduction of local Ang II. However, hepatic ACE
may be produced by inflammatory cells, activated stellate
cells, hepatocytes, and proliferating bile duct epithelial
cells.5,29 It is possible that aliskiren may have a direct inhib-
itory effect on ACE gene expression in these cells. Elucidation
of the exact mechanism of how aliskiren influences the hepatic
RAS requires further investigation.
It is generally believed that the conversion of locally generated
angiotensinogen to Ang I in the liver may occur via renal renin
from the circulation because the level of renin in normal or
cirrhotic livers has been perceived to be low.5We found that in the
liver perfusion study, sequential dosages of aliskiren treatment
inducedmore vasorelaxation and less hepatic production ofAng II
in the cirrhotic livers. Our data imply that aliskirenmight block the
conversionof angiotensinogenbyoccupying the active site of local
renin in the cirrhotic livers, leading to the reduction of localAng II.
In conclusion, our findings demonstrate that there is
a beneficial effect of aliskiren on portal pressure and intra-
hepatic resistance through reduction of Ang II production in
the cirrhotic liver. Direct renin inhibition may serve as
a potential and effective therapeutic strategy for the manage-
ment of portal hypertension.
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